These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2176932)
41. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766 [TBL] [Abstract][Full Text] [Related]
42. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR; Hickok JT; Rosenthal SN Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113 [TBL] [Abstract][Full Text] [Related]
43. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron. Goldsmith B Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626 [No Abstract] [Full Text] [Related]
44. Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P Semin Oncol; 1995 Aug; 22(4 Suppl 10):19-23. PubMed ID: 7570050 [No Abstract] [Full Text] [Related]
45. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Haga K; Inaba K; Shoji H; Morimoto Y; Fukuda T; Setoguchi M Jpn J Pharmacol; 1993 Nov; 63(3):377-83. PubMed ID: 8107329 [TBL] [Abstract][Full Text] [Related]
46. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358 [TBL] [Abstract][Full Text] [Related]
47. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group. Smith IE Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780 [TBL] [Abstract][Full Text] [Related]
48. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Chevallier B Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784 [TBL] [Abstract][Full Text] [Related]
50. Effect of granisetron on performance status during high-dose interferon therapy. Drapkin R; Barolo JL; Blower PR Oncology; 1999 Nov; 57(4):303-5. PubMed ID: 10575316 [TBL] [Abstract][Full Text] [Related]
52. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. Kang YK; Park YH; Ryoo BY; Bang YJ; Cho KS; Shin DB; Kim HC; Lee KH; Park YS; Lee KS; Heo DS; Kim SY; Cho EK; Lim HY; Kim WK; Lee JA; Kim TY; Lee JC; Yoon HJ; Kim NK J Int Med Res; 2002; 30(3):220-9. PubMed ID: 12166338 [TBL] [Abstract][Full Text] [Related]
53. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737 [TBL] [Abstract][Full Text] [Related]
54. Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Fukunaka N; Sagae S; Kudo R; Endo T; Hirafuji M; Minami M Gen Pharmacol; 1998 Nov; 31(5):775-81. PubMed ID: 9809477 [TBL] [Abstract][Full Text] [Related]
55. BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy. Joss RA; Richner J; Brunner KW; Rohrbach D; Pirovino M; Terrey JP; Upward J J Natl Cancer Inst; 1988 Oct; 80(16):1340-1. PubMed ID: 2845107 [No Abstract] [Full Text] [Related]
57. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. J Cancer Res Clin Oncol; 1993; 119(9):555-9. PubMed ID: 8392077 [TBL] [Abstract][Full Text] [Related]
58. [The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases]. Buiuc AI; Găleşanu MR Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):160-4. PubMed ID: 9455457 [TBL] [Abstract][Full Text] [Related]
59. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Cupissol DR; Serrou B; Caubel M Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782 [TBL] [Abstract][Full Text] [Related]
60. Caring for the cancer patient: managing emesis now. An interactive workshop. Proceedings of a satellite symposium to the 6th European Conference on Clinical Oncology. Florence, October 1991. Eur J Cancer; 1992; 28A Suppl 1():S1-44. PubMed ID: 1352697 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]